EUR/USD
1.16646
-0.015%
Gold
4591.90
-0.117%
Oil
59.992
0.580%
USD/JPY
158.920
0.482%
GBP/USD
1.34750
0.072%
GBP/JPY
214.151
0.562%
Real-time News
On January 13th, data from the China Automobile Dealers Association showed that in December 2025, the national used car market saw 1.8711 million transactions, a 7.15% increase month-on-month and a 1.53% decrease year-on-year, with a transaction value of 120.672 billion yuan. From January to December 2025, the cumulative used car transaction volume reached 20.108 million vehicles, a 2.52% increase year-on-year, with a cumulative transaction value of 1,289.79 billion yuan.Google will develop and manufacture high-end mobile phones in Vietnam this year.On January 13th, Bio-Thera Solutions announced that its second board of directors held its 18th meeting on October 8th, 2024, and approved the "Proposal on Signing an Authorization License, Production, Supply and Commercialization Agreement for BAT2206". According to the agreement, Bio-Thera Solutions recently received a one-time milestone payment of US$2.5 million from Jireh Pharmaceuticals. This payment further replenishes the companys cash reserves and supports the companys subsequent pipeline development and internationalization strategy. As of the date of this announcement, BAT2206 injection has been approved for marketing by the U.S. Food and Drug Administration and the European Medicines Agency, with the registered brand name STARJEMZA® in the U.S. and Usymro® in Europe; a marketing application has been submitted to the National Medical Products Administration of China and is currently under review.On January 13, Henlius Biotech (02696.HK) announced that its Biologics License Application (BLA) for its self-developed Hanbetai® (bevacizumab injection) has been accepted by the U.S. Food and Drug Administration. The indications covered by this application include: (1) metastatic colorectal cancer; (2) first-line treatment of unresectable locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel; (3) recurrent adult glioblastoma; (4) treatment of metastatic renal cell carcinoma in combination with interferon-α; (5) epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer; and (6) treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.On January 13th, Jingjia Microelectronics announced that it had signed a Strategic Cooperation Intent Agreement with Hangzhou Jingan Technology Co., Ltd. Based on equality, mutual benefit, and complementary advantages, the two parties will leverage Jingjias technological strengths in GPU and AISoC chips, combined with Jingan Technologys capabilities in system-level software and algorithms, to jointly promote deep product integration through comprehensive cooperation in branding, products, and technology. The two parties will establish a sustainable and in-depth partnership based on mutual trust. The cooperation will include, but is not limited to, products such as global situational awareness systems, intelligent control engines for unmanned equipment, intelligent sentry defense systems, and listening systems, providing comprehensive solutions for multiple fields including low-altitude economy, smart transportation, urban governance, key area protection, and integrated management of unmanned aerial vehicles.
